News

Blocking APOC1 protein can slow lymphoma cell growth
Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...
The Munich Eye3h
Inhibiting APOC1 Protein May Halt Lymphoma Cell Proliferation
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
The American Journal of Managed Care6d
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...
eLife1d
DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma
This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...
The American Journal of Managed Care1d
Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD
In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...
CURE18h
First Patient with CD5-Positive T-Cell Lymphoma Dosed with MB-105
The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.
The Manila Times9d
European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...